Lung Cancer Practice Review Issue 9
In this issue:
Australia bans vaping
Inhalable sensors may enable early lung cancer diagnosis with a urine test
APPLE: osimertinib vs gefitinib/osimertinib in advanced EGFR-mutated NSCLC
Rates of invasive procedures following lung cancer screening may be higher than thought
Osimertinib consolidation beneficial in inoperable EGFR-mutated NSCLC
Ficonalkib promising for ALK-positive NSCLC resistant to second-generation ALK TKIs
PBAC recommendations
Upcoming PBAC agenda
PBS listings
Updates from the FDA
ANORAK improves histopathological grading of lung adenocarcinoma
INSPIRE supports front-line iruplinalkib for ALK positive NSCLC
2024 TROG Annual Scientific Meeting
Mirtazapine may improve lung cancer-related anorexia
COVID-19 resources
Conferences & Workshops
Expert contributor
Dr Divyanshu (Divy) Dua
Dr. Divyanshu “Divy” Dua graduated from the Manipal Academy of Higher Education, India followed by fellowship of Royal Australasian College of Physicians. He trained in internal medicine and medical oncology in Australia followed by clinical fellowship in drug development, early phase trials and thoracic malignancies at the Guys Hospital in London as well as Sarah […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.